Results 141 to 150 of about 3,904 (178)

Risankizumab

Reactions Weekly
  +19 more sources

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials [PDF]

Lancet, The, 2022
BACKGROUND: Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease.
Brian Feagan, Filip Baert, Xiaomei Liao   +2 more
exaly   +2 more sources

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study [PDF]

Dermatologic Therapy, 2022
IL‐23‐inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness,
Angelo Ruggiero, Matteo Megna, Eleonora Cinelli   +2 more
exaly   +2 more sources

Risankizumab shows high efficacy and maintenance in improvement of response until week 52 [PDF]

Dermatologic Therapy, 2022
Risankizumab has been recently approved for moderate‐to‐severe plaque psoriasis; however, real‐life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience ...
Simone Ribero, Niccolo Siliquini, Marco Rubatto   +2 more
exaly   +2 more sources

Risankizumab

Reactions Weekly, 2022
  +6 more sources

Risankizumab

Hospital Pharmacy, 2019
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy and Therapeutics (P&T) Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
openaire   +2 more sources

Risankizumab

Reactions Weekly, 2023
  +6 more sources